“IMV, Inc. (IMV) reported positive interim results from Ph. II study of DPX-Survivac in combination with Merck’s Keytruda in relapsed/refractory Lymphoma (r/r DLBCL), thereby further building on the strength of efficacy noted in the prior update in 3Q18 and exceeded our expectation. While still an early read with only six evaluable patients at this cut-off point, one could begin to draw comparison to the 50-72% ORR (n=up to 100 patients) observed with CAR-T approaches from 40% ORR (n=16 patients) observed with antibody drug conjugate (ADC) approach from Roche that led to their respective FDA approvals in this difficult-to-treat B-cell hematological malignancy.”
According to TipRanks.com, Mamtani is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -6.3% and a 34.7% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Madrigal Pharmaceuticals Inc.
Currently, the analyst consensus on IMV Inc. is a Strong Buy with an average price target of $11.25, which is a 175.1% upside from current levels. In a report issued on June 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $11.50 price target.
Based on IMV Inc.’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.47 million. In comparison, last year the company had a GAAP net loss of $2.42 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.